Clarissa Pilkington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Clarissa Pilkington has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Lucy R. Wedderburn
University College London Great Ormond Street Institute of Child Health, London, UK
6 shared publications - Michael William Beresford
Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
4 shared publications - Adam M. Huber
IWK Health Centre and Dalhousie University, Halifax, Canada
2 shared publications - Angelo Ravelli
Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy
2 shared publications - Beatrice Goilav
Albert Einstein College of Medicine
2 shared publications - Caroline Ann Jones
Department of Paediatric Nephrology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
2 shared publications
Latest Publications
- Open Access
- 15 April 2020
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 22 (1) , 1-9
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Background: Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment. Methods: Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician’s global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman’s test for repeated measures analysis of variance. Results: Compared to baseline, there were improvements at 6 and 12 months in skin disease (χ2(2) = 15.52, p = 0.00043), global disease (χ2(2) = 8.14, p = 0.017) and muscle disease (CMAS χ2(2) = 17.02, p = 0.0002 and MMT χ2(2) = 10.56, p = 0.005) in infliximab patients. For patients who switched from infliximab to adalimumab, there was improvement in global disease activity (χ2(2) = 6.73, p = 0.03), and trends towards improvement in CMAS, MMT8 and modified DAS. The median initial prednisolone dose was 6 [0–10] mg, and final was 2.5 [0–7.5] mg (p < 0.0001). Fifty-four per cent of patients had a reduction in the number and/or size of calcinosis lesions. Twenty-five per cent switched their anti-TNF treatment from infliximab to adalimumab. 66.7%of the switches were to improve disease control, 26.7% due to adverse events and 6.6% due to patient preference. A total of 13.9 adverse reactions occurred in 100 patient-years, of which 5.7 were considered serious. Conclusion: Reductions in muscle and skin disease, including calcinosis, were seen following treatment with infliximab and adalimumab.
- 15 April 2020
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 22 (1) , 1-9
Open AccessRetrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Background: Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment. Methods: Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician’s global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman’s test for repeated measures analysis of variance. Results: Compared to baseline, there were improvements at 6 and 12 months in skin disease (χ2(2) = 15.52, p = 0.00043), global disease (χ2(2) = 8.14, p = 0.017) and muscle disease (CMAS χ2(2) = 17.02, p = 0.0002 and MMT χ2(2) = 10.56, p = 0.005) in infliximab patients. For patients who switched from infliximab to adalimumab, there was improvement in global disease activity (χ2(2) = 6.73, p = 0.03), and trends towards improvement in CMAS, MMT8 and modified DAS. The median initial prednisolone dose was 6 [0–10] mg, and final was 2.5 [0–7.5] mg (p < 0.0001). Fifty-four per cent of patients had a reduction in the number and/or size of calcinosis lesions. Twenty-five per cent switched their anti-TNF treatment from infliximab to adalimumab. 66.7%of the switches were to improve disease control, 26.7% due to adverse events and 6.6% due to patient preference. A total of 13.9 adverse reactions occurred in 100 patient-years, of which 5.7 were considered serious. Conclusion: Reductions in muscle and skin disease, including calcinosis, were seen following treatment with infliximab and adalimumab.
- 1 January 2019
- Published by Elsevier in Clinical Immunology
- Vol. 198, 71-78
A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity
- 1 January 2019
- Published by Elsevier in Clinical Immunology
- Vol. 198, 71-78
A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity
- Open Access
- 25 March 2018
- Published by Wiley in Arthritis & Rheumatology
- Vol. 70 (5) , 785-793
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
Objective: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical improvement in juvenile DM patients treated with CYC and model the efficacy of CYC treatment compared to no CYC treatment.Methods: Clinical data on skin, global, and muscle disease for patients recruited to the Juvenile DM Cohort and Biomarker Study were analyzed. Clinical improvement following CYC treatment was described using unadjusted analysis. Marginal structural models (MSMs) were used to model treatment efficacy and adjust for confounding by indication.Results: Compared to the start of CYC treatment, there were reductions at 6, 12, and 24 months in skin disease (P = 1.3 × 10‐10), global disease (P = 2.4 × 10‐8), and muscle disease (P = 8.0 × 10‐10) for 56 patients treated with CYC in unadjusted analysis. Limited evidence suggested a reduction in glucocorticoid dose (P = 0.047) in patients treated with CYC. MSM analysis showed reduced global disease and skin disease in patients who started an ~6‐month course of CYC treatment >12 months ago compared to patients never or not yet treated with CYC. In the treated patients, the modified skin Disease Activity Score for juvenile DM was 1.19 units lower (P = 0.0085) and the physician's global assessment was 0.66 units lower (P = 0.027). Minor adverse events were reported in 3 patients within 1 year of stopping CYC.Conclusion: Our findings indicate that CYC is efficacious with no short‐term side effects. Improvements in skin, global, and muscle disease were observed. Further studies are required to evaluate longer‐term side effects.
- 25 March 2018
- Published by Wiley in Arthritis & Rheumatology
- Vol. 70 (5) , 785-793
Open AccessEfficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
Objective: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical improvement in juvenile DM patients treated with CYC and model the efficacy of CYC treatment compared to no CYC treatment.Methods: Clinical data on skin, global, and muscle disease for patients recruited to the Juvenile DM Cohort and Biomarker Study were analyzed. Clinical improvement following CYC treatment was described using unadjusted analysis. Marginal structural models (MSMs) were used to model treatment efficacy and adjust for confounding by indication.Results: Compared to the start of CYC treatment, there were reductions at 6, 12, and 24 months in skin disease (P = 1.3 × 10‐10), global disease (P = 2.4 × 10‐8), and muscle disease (P = 8.0 × 10‐10) for 56 patients treated with CYC in unadjusted analysis. Limited evidence suggested a reduction in glucocorticoid dose (P = 0.047) in patients treated with CYC. MSM analysis showed reduced global disease and skin disease in patients who started an ~6‐month course of CYC treatment >12 months ago compared to patients never or not yet treated with CYC. In the treated patients, the modified skin Disease Activity Score for juvenile DM was 1.19 units lower (P = 0.0085) and the physician's global assessment was 0.66 units lower (P = 0.027). Minor adverse events were reported in 3 patients within 1 year of stopping CYC.Conclusion: Our findings indicate that CYC is efficacious with no short‐term side effects. Improvements in skin, global, and muscle disease were observed. Further studies are required to evaluate longer‐term side effects.
- Open Access
- 31 October 2017
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 15 (1) , 77
Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature
Anti-Signal Recognition Particle associated myopathy is a clinically and histopathologically distinct subgroup of Juvenile Idiopathic Inflammatory Myositis, which is under-recognised in children and fails to respond to conventional first line therapies. We present three cases where remission was successfully induced using combination therapy with intensive rehabilitation. Three new patients are reported. All 3 cases presented with profound, rapid-onset, proximal myopathy and markedly raised CK, but no rash. Histology revealed a destructive myopathy characterized by scattered atrophic and necrotic fibres with little or no inflammatory infiltrate. All 3 patients responded to induction with cyclophosphamide, IVIG and rituximab, in conjunction with intensive physiotherapy and methotrexate as the maintenance agent. Our patients regained near-normal strength (MMT > 70/80), in contrast with the current literature where >50% of cases reported severe residual weakness. A literature search on paediatric anti-SRP myositis was performed to June 2016; PubMed was screened using a combination of the following terms: signal recognition particle, autoantibodies, antibodies, myositis, muscular diseases, skeletal muscle, childhood, paediatric, juvenile. Articles in a foreign language were excluded. Nine case studies were found. This paper supports the hypothesis that anti-SRP myositis is distinct from other JIIM. It is an important differential to JDM and should be considered where there is severe weakness without rash or if highly elevated muscle enzymes (CK > 10,000 U/l) are found. Early identification is essential to initiate aggressive medical and physical therapy. Greater international collaboration and long-term follow-up data is needed to establish the most effective treatment strategy for this rare group of patients.
- 31 October 2017
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 15 (1) , 77
Open AccessEffective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature
Anti-Signal Recognition Particle associated myopathy is a clinically and histopathologically distinct subgroup of Juvenile Idiopathic Inflammatory Myositis, which is under-recognised in children and fails to respond to conventional first line therapies. We present three cases where remission was successfully induced using combination therapy with intensive rehabilitation. Three new patients are reported. All 3 cases presented with profound, rapid-onset, proximal myopathy and markedly raised CK, but no rash. Histology revealed a destructive myopathy characterized by scattered atrophic and necrotic fibres with little or no inflammatory infiltrate. All 3 patients responded to induction with cyclophosphamide, IVIG and rituximab, in conjunction with intensive physiotherapy and methotrexate as the maintenance agent. Our patients regained near-normal strength (MMT > 70/80), in contrast with the current literature where >50% of cases reported severe residual weakness. A literature search on paediatric anti-SRP myositis was performed to June 2016; PubMed was screened using a combination of the following terms: signal recognition particle, autoantibodies, antibodies, myositis, muscular diseases, skeletal muscle, childhood, paediatric, juvenile. Articles in a foreign language were excluded. Nine case studies were found. This paper supports the hypothesis that anti-SRP myositis is distinct from other JIIM. It is an important differential to JDM and should be considered where there is severe weakness without rash or if highly elevated muscle enzymes (CK > 10,000 U/l) are found. Early identification is essential to initiate aggressive medical and physical therapy. Greater international collaboration and long-term follow-up data is needed to establish the most effective treatment strategy for this rare group of patients.
- Open Access
- 9 December 2016
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 14 (1) , 1-5
Macrophage activation syndrome triggered by coeliac disease: a unique case report
Macrophage activation syndrome is described as a “clinical syndrome of hyperinflammation resulting in an uncontrolled and ineffective immune response” in the context of an autoinflammatory or rheumatic disease. Current associations of macrophage activation syndrome with autoimmune disease most notably include a host of rheumatological conditions and inflammatory bowel disease. Epidemiological studies have shown that macrophage activation syndrome is precipitated by autoimmune disease more commonly than previously thought. Diagnosing the precipitating factor is essential for effective treatment and prognosis. We report a case of a six year old girl with coeliac disease diagnosed after two episodes of secondary haemophagocytic lymphohistiocytosis. Her condition only responded to treatment once the patient was placed on a gluten free diet. Further immunological testing confirmed anti-transglutaminase and anti-endomysial antibodies, however histological biopsy was deemed inappropriate due to the severity of her condition. She has remained stable with no further episodes of macrophage activation syndrome since commencing a gluten free diet. This case report is the first literature that links macrophage activation syndrome to coeliac disease and highlights the challenge of diagnosing coeliac disease with unusual features such as associated prolonged fever. Clinicians should have a low threshold for screening children with other autoimmune diseases for coeliac disease.
- 9 December 2016
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 14 (1) , 1-5
Open AccessMacrophage activation syndrome triggered by coeliac disease: a unique case report
Macrophage activation syndrome is described as a “clinical syndrome of hyperinflammation resulting in an uncontrolled and ineffective immune response” in the context of an autoinflammatory or rheumatic disease. Current associations of macrophage activation syndrome with autoimmune disease most notably include a host of rheumatological conditions and inflammatory bowel disease. Epidemiological studies have shown that macrophage activation syndrome is precipitated by autoimmune disease more commonly than previously thought. Diagnosing the precipitating factor is essential for effective treatment and prognosis. We report a case of a six year old girl with coeliac disease diagnosed after two episodes of secondary haemophagocytic lymphohistiocytosis. Her condition only responded to treatment once the patient was placed on a gluten free diet. Further immunological testing confirmed anti-transglutaminase and anti-endomysial antibodies, however histological biopsy was deemed inappropriate due to the severity of her condition. She has remained stable with no further episodes of macrophage activation syndrome since commencing a gluten free diet. This case report is the first literature that links macrophage activation syndrome to coeliac disease and highlights the challenge of diagnosing coeliac disease with unusual features such as associated prolonged fever. Clinicians should have a low threshold for screening children with other autoimmune diseases for coeliac disease.
- Open Access
- 3 September 2016
- Published by Springer Nature in Pediatric Nephrology
- Vol. 32 (2) , 283-295
International validation of a urinary biomarker panel for identification of active lupus nephritis in children
Background Conventional markers of juvenile-onset systemic lupus erythematosus (JSLE) disease activity fail to adequately identify lupus nephritis (LN). While individual novel urine biomarkers are good at detecting LN flares, biomarker panels may improve diagnostic accuracy. The aim of this study was to assess the performance of a biomarker panel to identify active LN in two international JSLE cohorts. Methods Novel urinary biomarkers, namely vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein 1 (MCP-1), lipocalin-like prostaglandin D synthase (LPGDS), transferrin (TF), ceruloplasmin, alpha-1-acid glycoprotein (AGP) and neutrophil gelatinase-associated lipocalin (NGAL), were quantified in a cross-sectional study that included participants of the UK JSLE Cohort Study (Cohort 1) and validated within the Einstein Lupus Cohort (Cohort 2). Binary logistic regression modelling and receiver operating characteristic curve analysis [area under the curve (AUC)] were used to identify and assess combinations of biomarkers for diagnostic accuracy. Results A total of 91 JSLE patients were recruited across both cohorts, of whom 31 (34 %) had active LN and 60 (66 %) had no LN. Urinary AGP, ceruloplasmin, VCAM-1, MCP-1 and LPGDS levels were significantly higher in those patients with active LN than in non-LN patients [all corrected p values (p c) < 0.05] across both cohorts. Urinary TF also differed between patient groups in Cohort 2 (p c = 0.001). Within Cohort 1, the optimal biomarker panel included AGP, ceruloplasmin, LPGDS and TF (AUC 0.920 for active LN identification). These results were validated in Cohort 2, with the same markers resulting in the optimal urine biomarker panel (AUC 0.991). Conclusion In two international JSLE cohorts, urinary AGP, ceruloplasmin, LPGDS and TF demonstrate an ‘excellent’ ability for accurately identifying active LN in children.
- 3 September 2016
- Published by Springer Nature in Pediatric Nephrology
- Vol. 32 (2) , 283-295
Open AccessInternational validation of a urinary biomarker panel for identification of active lupus nephritis in children
Background Conventional markers of juvenile-onset systemic lupus erythematosus (JSLE) disease activity fail to adequately identify lupus nephritis (LN). While individual novel urine biomarkers are good at detecting LN flares, biomarker panels may improve diagnostic accuracy. The aim of this study was to assess the performance of a biomarker panel to identify active LN in two international JSLE cohorts. Methods Novel urinary biomarkers, namely vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein 1 (MCP-1), lipocalin-like prostaglandin D synthase (LPGDS), transferrin (TF), ceruloplasmin, alpha-1-acid glycoprotein (AGP) and neutrophil gelatinase-associated lipocalin (NGAL), were quantified in a cross-sectional study that included participants of the UK JSLE Cohort Study (Cohort 1) and validated within the Einstein Lupus Cohort (Cohort 2). Binary logistic regression modelling and receiver operating characteristic curve analysis [area under the curve (AUC)] were used to identify and assess combinations of biomarkers for diagnostic accuracy. Results A total of 91 JSLE patients were recruited across both cohorts, of whom 31 (34 %) had active LN and 60 (66 %) had no LN. Urinary AGP, ceruloplasmin, VCAM-1, MCP-1 and LPGDS levels were significantly higher in those patients with active LN than in non-LN patients [all corrected p values (p c) < 0.05] across both cohorts. Urinary TF also differed between patient groups in Cohort 2 (p c = 0.001). Within Cohort 1, the optimal biomarker panel included AGP, ceruloplasmin, LPGDS and TF (AUC 0.920 for active LN identification). These results were validated in Cohort 2, with the same markers resulting in the optimal urine biomarker panel (AUC 0.991). Conclusion In two international JSLE cohorts, urinary AGP, ceruloplasmin, LPGDS and TF demonstrate an ‘excellent’ ability for accurately identifying active LN in children.
- Open Access
- 12 June 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-15
Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use
Juvenile dermatomyositis (JDM) is a rare autoimmune inflammatory disorder associated with significant morbidity and mortality. International collaboration is necessary to better understand the pathogenesis of the disease, response to treatment and long-term outcome. To aid international collaboration, it is essential to have a core set of data that all researchers and clinicians collect in a standardised way for clinical purposes and for research. This should include demographic details, diagnostic data and measures of disease activity, investigations and treatment. Variables in existing clinical registries have been compared to produce a provisional data set for JDM. We now aim to develop this into a consensus-approved minimum core dataset, tested in a wider setting, with the objective of achieving international agreement. A two-stage bespoke Delphi-process will engage the opinion of a large number of key stakeholders through Email distribution via established international paediatric rheumatology and myositis organisations. This, together with a formalised patient/parent participation process will help inform a consensus meeting of international experts that will utilise a nominal group technique (NGT). The resulting proposed minimal dataset will be tested for feasibility within existing database infrastructures. The developed minimal dataset will be sent to all internationally representative collaborators for final comment. The participants of the expert consensus group will be asked to draw together these comments, ratify and ‘sign off’ the final minimal dataset. An internationally agreed minimal dataset has the potential to significantly enhance collaboration, allow effective communication between groups, provide a minimal standard of care and enable analysis of the largest possible number of JDM patients to provide a greater understanding of this disease. The final approved minimum core dataset could be rapidly incorporated into national and international collaborative efforts, including existing prospective databases, and be available for use in randomised controlled trials and for treatment/protocol comparisons in cohort studies.
- 12 June 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-15
Open AccessDevelopment of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use
Juvenile dermatomyositis (JDM) is a rare autoimmune inflammatory disorder associated with significant morbidity and mortality. International collaboration is necessary to better understand the pathogenesis of the disease, response to treatment and long-term outcome. To aid international collaboration, it is essential to have a core set of data that all researchers and clinicians collect in a standardised way for clinical purposes and for research. This should include demographic details, diagnostic data and measures of disease activity, investigations and treatment. Variables in existing clinical registries have been compared to produce a provisional data set for JDM. We now aim to develop this into a consensus-approved minimum core dataset, tested in a wider setting, with the objective of achieving international agreement. A two-stage bespoke Delphi-process will engage the opinion of a large number of key stakeholders through Email distribution via established international paediatric rheumatology and myositis organisations. This, together with a formalised patient/parent participation process will help inform a consensus meeting of international experts that will utilise a nominal group technique (NGT). The resulting proposed minimal dataset will be tested for feasibility within existing database infrastructures. The developed minimal dataset will be sent to all internationally representative collaborators for final comment. The participants of the expert consensus group will be asked to draw together these comments, ratify and ‘sign off’ the final minimal dataset. An internationally agreed minimal dataset has the potential to significantly enhance collaboration, allow effective communication between groups, provide a minimal standard of care and enable analysis of the largest possible number of JDM patients to provide a greater understanding of this disease. The final approved minimum core dataset could be rapidly incorporated into national and international collaborative efforts, including existing prospective databases, and be available for use in randomised controlled trials and for treatment/protocol comparisons in cohort studies.
- Open Access
- 21 July 2014
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 12 (1) , 31
Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research
Juvenile dermatomyositis (JDM) is a rare but severe autoimmune inflammatory myositis of childhood. International collaboration is essential in order to undertake clinical trials, understand the disease and improve long-term outcome. The aim of this study was to propose from existing collaborative initiatives a preliminary minimal dataset for JDM. This will form the basis of the future development of an international consensus-approved minimum core dataset to be used both in clinical care and inform research, allowing integration of data between centres.
- 21 July 2014
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 12 (1) , 31
Open AccessDeveloping a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research
Juvenile dermatomyositis (JDM) is a rare but severe autoimmune inflammatory myositis of childhood. International collaboration is essential in order to undertake clinical trials, understand the disease and improve long-term outcome. The aim of this study was to propose from existing collaborative initiatives a preliminary minimal dataset for JDM. This will form the basis of the future development of an international consensus-approved minimum core dataset to be used both in clinical care and inform research, allowing integration of data between centres.
- Open Access
- 2 July 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (4) , R138
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study
Introduction: The aim of this study was to define the frequency and associated clinical phenotype of anti-MDA5 autoantibodies in a large UK based, predominantly Caucasian, cohort of patients with juvenile dermatomyositis (JDM). Methods: Serum samples and clinical data were obtained from 285 patients with JDM recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-MDA5 antibodies was determined by immunoprecipitation and confirmed by ELISA using recombinant MDA5 protein. Results were compared with matched clinical data, muscle biopsies (scored by an experienced paediatric neuropathologist) and chest imaging (reviewed by an experienced paediatric radiologist). Results: Anti-MDA5 antibodies were identified in 7.4% of JDM patients and were associated with a distinct clinical phenotype including skin ulceration (P = 0.03) oral ulceration (P = 0.01), arthritis (P P = 0.03)) and histologically (as determined by a lower JDM muscle biopsy score (P P = 0.02). A total of 4 out of 21 children with anti-MDA5 had interstitial lung disease; none had rapidly progressive interstitial lung disease. Conclusions: Anti-MDA5 antibodies can be identified in a small but significant proportion of patients with JDM and identify a distinctive clinical sub-group. Screening for anti-MDA5 autoantibodies at diagnosis would be useful to guide further investigation for lung disease, inform on prognosis and potentially confirm the diagnosis, as subtle biopsy changes could otherwise be missed.
- 2 July 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (4) , R138
Open AccessAnti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study
Introduction: The aim of this study was to define the frequency and associated clinical phenotype of anti-MDA5 autoantibodies in a large UK based, predominantly Caucasian, cohort of patients with juvenile dermatomyositis (JDM). Methods: Serum samples and clinical data were obtained from 285 patients with JDM recruited to the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-MDA5 antibodies was determined by immunoprecipitation and confirmed by ELISA using recombinant MDA5 protein. Results were compared with matched clinical data, muscle biopsies (scored by an experienced paediatric neuropathologist) and chest imaging (reviewed by an experienced paediatric radiologist). Results: Anti-MDA5 antibodies were identified in 7.4% of JDM patients and were associated with a distinct clinical phenotype including skin ulceration (P = 0.03) oral ulceration (P = 0.01), arthritis (P P = 0.03)) and histologically (as determined by a lower JDM muscle biopsy score (P P = 0.02). A total of 4 out of 21 children with anti-MDA5 had interstitial lung disease; none had rapidly progressive interstitial lung disease. Conclusions: Anti-MDA5 antibodies can be identified in a small but significant proportion of patients with JDM and identify a distinctive clinical sub-group. Screening for anti-MDA5 autoantibodies at diagnosis would be useful to guide further investigation for lung disease, inform on prognosis and potentially confirm the diagnosis, as subtle biopsy changes could otherwise be missed.
- Open Access
- 1 June 2013
- Published by BMJ in Archives of Disease in Childhood
- Vol. 98 (Suppl 1) , A1-A2
P03 Novel Urine Biomarkers For Monitoring Disease Activity in Juvenile Lupus Nephritis: A Prospective Longitudinal Validation Study
Background Systemic Lupus Erythematosus (JSLE) is a severe autoimmune condition with lupus nephritis (LN) seen more frequently in juvenile disease where up to 80% have renal involvement [1]. The renal biopsy is crucial for diagnosis and classification but has a limited role in monitoring. Current methods of monitoring renal disease activity over time rely on a variety of standard laboratory markers and the use of disease activity tools such as the British Isles Lupus Assessment Group index score (BILAG). Improving methods of monitoring and predicting disease activity may improve the long-term renal outcome. Aims and methods This prospective longitudinal study aimed to identify whether standard and/or novel biomarkers are useful for monitoring and predicting LN disease activity. Using patients recruited to the UK JSLE study, urine and blood samples were collected during routine clinical reviews. The study had full ethical approval. Results The JSLE cohort (n = 64), seen at 3 (interquartile range IQR: 2–5) clinical reviews over 364 (182–532) days were aged 14.1 (11.8–15.8) years and 80% female. Active renal episodes (23% total; renal BILAG A/B) had significantly increased concentration of; monocyte chemoattractant protein 1 (MCP1), neutrophil gelatinase associated lipocalin (NGAL), erythrocyte sedimentation rate, anti-double stranded DNA, urine albumin:creatinine ratio (UACR), creatinine, and reduced complement 3 (C3), C4 and lymphocytes. Cross sectional multivariate analysis demonstrated MCP1 and C3 as independent variables (p < 0.001) for active renal disease. Longitudinally, MCP1 was an excellent predictor of improved renal disease (area under the curve AUC: 0.81; p = 0.013; concentration 343pg/ml, specificity 71%, sensitivity 70%); NGAL was a good predictor of worsened renal disease activity (AUC 0.76; p = 0.04; concentration 30ng/ml, specificity 60%, sensitivity 61%). Standard markers could not predict disease activity changes. Conclusion Novel biomarkers (MCP1, NGAL) are able to predict changes in JSLE related renal disease activity. Biomarker-led monitoring may facilitate earlier intervention to prevent renal damage. The development of point of care biomarker testing is now in progress. Reference Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J et al. Arthritis Rheum 2012.
- 1 June 2013
- Published by BMJ in Archives of Disease in Childhood
- Vol. 98 (Suppl 1) , A1-A2
Open AccessP03 Novel Urine Biomarkers For Monitoring Disease Activity in Juvenile Lupus Nephritis: A Prospective Longitudinal Validation Study
Background Systemic Lupus Erythematosus (JSLE) is a severe autoimmune condition with lupus nephritis (LN) seen more frequently in juvenile disease where up to 80% have renal involvement [1]. The renal biopsy is crucial for diagnosis and classification but has a limited role in monitoring. Current methods of monitoring renal disease activity over time rely on a variety of standard laboratory markers and the use of disease activity tools such as the British Isles Lupus Assessment Group index score (BILAG). Improving methods of monitoring and predicting disease activity may improve the long-term renal outcome. Aims and methods This prospective longitudinal study aimed to identify whether standard and/or novel biomarkers are useful for monitoring and predicting LN disease activity. Using patients recruited to the UK JSLE study, urine and blood samples were collected during routine clinical reviews. The study had full ethical approval. Results The JSLE cohort (n = 64), seen at 3 (interquartile range IQR: 2–5) clinical reviews over 364 (182–532) days were aged 14.1 (11.8–15.8) years and 80% female. Active renal episodes (23% total; renal BILAG A/B) had significantly increased concentration of; monocyte chemoattractant protein 1 (MCP1), neutrophil gelatinase associated lipocalin (NGAL), erythrocyte sedimentation rate, anti-double stranded DNA, urine albumin:creatinine ratio (UACR), creatinine, and reduced complement 3 (C3), C4 and lymphocytes. Cross sectional multivariate analysis demonstrated MCP1 and C3 as independent variables (p < 0.001) for active renal disease. Longitudinally, MCP1 was an excellent predictor of improved renal disease (area under the curve AUC: 0.81; p = 0.013; concentration 343pg/ml, specificity 71%, sensitivity 70%); NGAL was a good predictor of worsened renal disease activity (AUC 0.76; p = 0.04; concentration 30ng/ml, specificity 60%, sensitivity 61%). Standard markers could not predict disease activity changes. Conclusion Novel biomarkers (MCP1, NGAL) are able to predict changes in JSLE related renal disease activity. Biomarker-led monitoring may facilitate earlier intervention to prevent renal damage. The development of point of care biomarker testing is now in progress. Reference Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J et al. Arthritis Rheum 2012.